Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "PLI"

3330 News Found

Genmab to acquire Merus for $8 billion
News | October 03, 2025

Genmab to acquire Merus for $8 billion

Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio


Lupin receives FDA approval Rivaroxaban for oral suspension
Drug Approval | October 01, 2025

Lupin receives FDA approval Rivaroxaban for oral suspension

The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India


DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future
Startup | October 01, 2025

DPIIT and Thermo Fisher Scientific launch BioVerse challenge to fast-track India’s biotech future

India currently hosts more than 10,075 biotech startups


AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
Drug Approval | October 01, 2025

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer

BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma


BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu
News | September 30, 2025

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price


Brenntag showcases innovations in beauty and personal care at Indonesia Cosmetic Ingredients 2025
Supply Chain | September 30, 2025

Brenntag showcases innovations in beauty and personal care at Indonesia Cosmetic Ingredients 2025

Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs


FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia
News | September 30, 2025

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia

FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses


AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
News | September 29, 2025

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs